This prospective study included 63 patients with advanced NSCLC who received PD‐1 monoclonal antibody therapy, and 44 patients who could eventually provide sufficient tissue samples for the gene panel testing. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.